Clinical trial
A 12-month, Randomized, Single-blind, Placebo-controlled Exposure-response Study of TCD601 (Siplizumab) in New Onset Type 1 Diabetes Patients (STRIDE)
NCT06025110 is registered in ClinicalTrials.gov with ITB-Med LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A 12-month, Randomized, Single-blind, Placebo-controlled Exposure-response Study of TCD601 (Siplizumab) in New Onset Type 1 Diabetes Patients (STRIDE)
- Lead sponsor
- ITB-Med LLC
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- January 23, 2023
- Completion date
- July 24, 2025
- Enrollment
- 9 (actual)
- Sites
- 26
Conditions
As the registry lists them; a condition with its own page is linked.